RUMORED BUZZ ON ABBV-744 FOR SMALL CELL LUNG CANCER RESEARCH

In Section C, contributors will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment until eventually condition progression or maybe the individuals are not able to tolerate the study drugs.- "Our study revealed the essential function in the KLF16/MYC regulatory axis in m